

PCTWORLD INTELLECTUAL PROPE
International Bi

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9606614A1

(51) International Patent Classification ⁶ : A61K 31/505, 31/52, C07D 239/02, 473/00	A1	(11) International Publication Number: WO 96/06614 (43) International Publication Date: 7 March 1996 (07.03.96)
---	----	---

(21) International Application Number: PCT/US95/10943 (22) International Filing Date: 30 August 1995 (30.08.95) (30) Priority Data: 08/298,011 30 August 1994 (30.08.94) US (71) Applicant: UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER [US/US]; 55 Lake Avenue North, Worcester, MA 01655 (US). (72) Inventors: BROWN, Neal, C.; 335 Crawford Street, Northboro, MA 01532 (US). WRIGHT, George; 298 Highland Street, Worcester, MA 01601 (US). (74) Agent: FASSE, J., Peter; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).	(81) Designated States: AU, BG, BR, CA, CN, CZ, FI, HU, IS, JP, KP, KR, MX, NO, NZ, PL, RO, RU, SD, SG, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.
--	---

(54) Title: NOVEL ANTIBIOTIC COMPOUNDS AND METHODS TO TREAT GRAM-POSITIVE BACTERIAL AND MYCOPLASMA INFECTIONS

(57) Abstract

A method of inhibiting replication of mycoplasmal and Gram-positive bacteria is described. Useful new compounds for *in vivo* and *in vitro* inhibition and therapy for infections utilizing HPURa-like compounds are also provided. These include a number of novel 3-substituted uracil and isocytosine compounds, and 10-substituted guanine and adenine compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NOVEL ANTIBIOTIC COMPOUNDS AND METHODS TO TREAT GRAM-
POSITIVE BACTERIAL AND MYCOPLASMAL INFECTIONS

5 Statement as to Federally Sponsored Research

This work was supported in part by the United States government, National Institute of Health Grants GM21747 and GM45330. The government may have certain rights in the invention.

10 Background of the Invention

The invention relates to mycoplasma and Gram positive bacterial infections.

Gram-positive eubacteria contain three distinct DNA polymerase-exonucleases ("pol-exos"): Pol I, Pol II, and
15 Pol III. Gram-positive Pol III is an enzyme which is absolutely required for the replicative synthesis of DNA that accompanies the cyclical duplication of the host chromosome. The Gram-positive Pol IIIs are the exclusive targets of the Gram-positive-selective 'HPUra' (6-(p-
20 Hydroxyphenylazo)-uracil) class of antimicrobial agents, i.e., HPUra-like compounds. These agents exert their action by mimicking purine deoxyribonucleoside5-triphosphates and physically inhibiting the DNA polymerases.

All known mycoplasmata are parasites of humans,
25 vertebrates, plants, and arthropods. Species known or suspected to be human pathogens include *M. pneumoniae*, *M. genitalium*, *M. penetrans*, and, in AIDS patients especially, *M. fermentans*, strain incognitus. *Mycoplasma* infections in humans and animals are generally of a chronic nature and
30 host immune reactions appear to play a major role in the pathogenesis of such infections. Especially problematic are autoimmunogenic responses elicited by mycoplasmal infections

(e.g., rheumatoid-like arthritis, central nervous system symptoms and other types of organ dysfunction).

Mycoplasmata are the smallest and simplest prokaryotes capable of self-replication. They have arisen from conventional Gram-positive bacteria via rapid, degenerative evolution, apparently resulting in significant simplification of the typical Gram-positive genome. A mycoplasmal genome may be as small as 600 kb (but may be as large as 1700 kb) and carry fewer than 500 genes (about one fifth the number of genes as in *E. coli*). This simplified existence is made possible by parasitism.

It is thought that the genome reduction of mycoplasmata has affected the DNA polymerase family of enzymes, reducing the three exo-positive enzymes found in Gram-positive bacteria to a single exo-deficient species (Boxer et al., Biochemistry, 18:4742-49 (1979); Maurel et al., Res. Microbiol., 140:191-205 (1989); Mills et al., J. Bacteriol., 132:641-49 (1977)).

Previous investigations have identified only a single DNA polymerase in *Mycoplasma*. The enzyme from *Mycoplasma orale* has been purified and found to consist of a single peptide of 103-116 kDa, and a polymerase of the same size has been found in *Mycoplasma hyorhinis*. A 98 kDa polymerase also has been found in *Mycoplasma mycoides*. In contrast to the prototypic Gram-positive- and Gram-negative-specific pols I and II, both of which integrate the activity of at least one exo (3'-5' and/or 5'-3'), none of the previously described mycoplasmal enzymes is exo-positive.

Summary of the Invention

We have identified compounds which inhibit Gram-positive bacterial and *Mycoplasma* DNA polymerase III and thus inhibit the growth of bacteria and mycoplasmata. New compounds are provided for use in the inhibition of both

mycoplasma and Gram-positive bacteria. In addition, we provide methods for using both the new compounds and some previously known compounds for the inhibition of mycoplasma and Gram-positive bacterial cells.


5 Accordingly, the invention features a method to inhibit the replication of mycoplasmal cells *in vivo* and *in vitro*. This method involves administering, in an amount sufficient to be effective for inhibition, compounds of the invention or any other "HPUra-like" deoxyribonucleotide
10 analog which inhibits the activity of the enzyme DNA polymerase III (e.g., pyrimidine or purine derivatives, 2-substituted dATP and N²-substituted dGTP analogs, ribo-, 2'-deoxyribo-, arabino-, 2',3'-dideoxy- or acyclo-nucleotides, N⁶-substituted 6-aminopyrimidines and N²-substituted 2-
15 aminopurines) to contact the cells.

By "inhibiting" is meant reducing the cellular growth rate by at least 80%, more preferably 90%, even more preferably 95% and, most preferably by 99% or more. The degree of inhibition may be ascertained by an *in vitro*
20 growth assay (e.g., by standard liquid culture techniques, the relative number of other colony forming units on an again MIC plate (supra) or dose-response experiments). Compounds showing inhibition of colony formation at a suitable (minimal inhibitory concentration) LDSO will be
25 useful for further examination as therapeutic agents.


By "effective amount" of a compound is meant an amount which, when administered *in vivo* or *in vitro*, will achieve the above-stated levels of inhibition.

Another featured aspect is a method to inhibit
30 growth of Gram-positive bacteria *in vivo* or *in vitro* by administering, in an amount sufficient to be effective for

inhibition, compounds of the invention which have the following general formulae:



- 5 wherein R_1 is $(CH_2)_nOH$, $CH_2CHOHCH_2OH$, $CH_2CHOHCH_3$, $(CH_2)_mCO_2H$, or $(CH_2)_mNH_2$, n is 2, 3, 4, or 5 and m is 1, 2, 3, or 4; and R_2 is an indanyl,



- 10 where R_3 and R_4 are H, alkyl, halo, or any other hydrophobic constituents.

- In preferred embodiments of both methods, the treatment is administered to an animal (e.g., swine, chicken, or other commercially relevant livestock) or to a human patient which has been diagnosed with a mycoplasmal or Gram-positive bacterial infection. In preferred
15 embodiments, the compounds may be administered to the animal

or human to prevent a mycoplasmal or Gram-positive bacterial infection, particularly in an animal or human which is susceptible to such infections (e.g., a human patient with AIDS or one who has recently undergone a medical procedure.


- 5 In other preferred embodiments, the treatment is administered to cultured eukaryotic cells, either those that have a mycoplasmal or Gram positive bacterial infection, or to prevent such an infection (e.g., prophylactic treatment). Culture medium may be prepared commercially to contain
10 compounds of the invention.

In preferred embodiments, the compounds used in the methods are one or more of the following compounds:


- A) 3-(2-Hydroxyethyl)-6-(5-indanylamino)uracil, HE-TMAU ("TMA" indicates 5-indanylamino, also referred to as 3,
15 4-trimethylene anilino);
B) 3-(2-Hydroxyethyl)-6-(5-indanylamino)isocytosine, HE-TMAiC;
C) 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylanilino)uracil, HE-EMAU;
20 D) 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylanilino)isocytosine, HE-EMAiC;
E) 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino)uracil, HE-DCAU;
F) 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino)
25 isocytosine, HE-DCAiC;
G) 3-(4-Hydroxybutyl)-6-(5-indanylamino)uracil, HB-TMAU;
H) 3-(4-Hydroxybutyl)-6-(5-indanylamino)isocytosine, HB-TMAiC;
30 I) 3-(Carboxymethyl)-6-(5-indanylamino)uracil, CM-TMAU;
J) 3-(2-Aminoethyl)-6-(5-indanylamino)uracil, AE-TMAU;

- K) 9-(2-Hydroxyethyl)-N²-(5-indanyl)guanine, HE-TMPG;
- L) 9-(2-Hydroxyethyl)-2-(5-indanylamino)adenine, HE-TMAA;
- 5 M) 9-(2-Hydroxyethyl)-N²-(3-ethyl-4-methylphenyl)guanine, HE-EMPG;
- N) 9-(2-Hydroxyethyl)-2-(3-ethyl-4-methylanilino)adenine, HE-EMAA;
- O) 9-(2-Hydroxyethyl)-N²-(3,4-dichlorobenzyl)guanine, HE-DCBG;
- 10 P) 9-(2-Hydroxyethyl)-2-(3,4-dichlorobenzylamino)adenine, HE-DCBA;
- Q) 9-(4-Hydroxybutyl)-N²-(3,4-dichlorobenzyl)guanine, HB-DCBG;
- 15 R) 9-(4-Hydroxybutyl)-2-(3,4-dichlorobenzylamino)adenine, HB-DCBA;
- S) 9-(2-Carboxyethyl)-N²-(3,4-dichlorobenzyl)guanine, CE-DCBG; and
- T) 9-(2-Aminoethyl)-N²-(3,4-dichlorobenzyl)guanine, AE-DCBG.
- 20

The invention also features 3-substituted uracil and isocytosine compounds or their pharmaceutically acceptable salts having the general formulae:




Uracils



Isocytosines

where R₁ in both uracils and isocytosines is (CH₂)_nOH, CH₂CHOHCH₂OH, CH₂CHOHCH₃, (CH₂)_mCO₂H, or (CH₂)_nNH₂, n is 2, 3, 4, or 5 and m is 1, 2, 3, or 4; and R₂ is




where R_3 and R_4 are H, alkyl, halo, or any other hydrophobic constituents (e.g., CH_3 , C_2H_5 , F, Cl, Br, and $(\text{CH}_2)_3$).


5 Preferred 3-substituted uracil and isocytosine compounds to be used in the invention are:

- A) 3-(2-Hydroxyethyl)-6-(5-indanylamino)uracil, HE-TMAU (TMA indicates to 5-indanylamino or 3,4-trimethylene-anilino);
- 10 B) 3-(2-Hydroxyethyl)-6-(5-indanylamino) isocytosine, HE-TMAiC;
- C) 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylanilino) uracil, HE-EMAU;
- D) 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylahilino) 15 isocytosine, HE-EMAiC;
- E) 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino) uracil, HE-DCAU;
- F) 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino) isocytosine, HE-DCAiC;
- 20 G) 3-(4-Hydroxybutyl)-6-(5-indanylamino)uracil, HB-TMAU;
- H) 3-(4-Hydroxybutyl)-6-(5-indanylamino) isocytosine, HB-TMAiC;
- I) 3-(Carboxymethyl)-6-(5-indanylamino)uracil, CM- 25 TMAU; and
- J) 3-(Aminoethyl)6-(5-indanylamino)uracil, AE-TMAU

Another aspect of the invention features 9-substituted guanine and adenine compounds of the general formulae:




Guanines




Adenines

where R_1 in both the guanine and adenine compounds is $(CH_2)_nOH$, $CH_2CHOHCH_2OH$, $CH_2CHOHCH_3$, $(CH_2)_mCO_2H$, or $(CH_2)_mNH_2$, n is 2, 3, 4, or 5 and m is 1, 2, 3, or 4; and R_2 is



or



where R_3 and R_4 are H, alkyl, halo, or any other hydrophobic constituents, e.g., CH_3 , C_2H_5 , F, Cl, Br, and $(CH_2)_3$.

10 Preferred 9-substituted guanine and adenine compounds for use in the invention are:

- A) 9-(2-Hydroxyethyl)- N^2 -(5-indanyl)guanine, HE-TMPG;
- B) 9-(2-Hydroxyethyl)-2-(5-indanylamino)adenine, HE-TMAA;
- 15 C) 9-(2-Hydroxyethyl)- N^2 -(3-ethyl-4-methylphenyl)guanine, HE-EMPG;
- D) 9-(2-Hydroxyethyl)-2-(3-ethyl-4-methylanilino)adenine, HE-EMAA;
- E) 9-(2-Hydroxyethyl)- N^2 -(3,4-dichlorobenzyl)guanine, HE-DCBG;
- 20 F) 9-(2-Hydroxyethyl)-2-(3,4-dichlorobenzylamino)adenine, HE-DCBA;
- G) 9-(4-Hydroxybutyl)- N^2 -(3,4-dichlorobenzyl)guanine, HB-DCBG;
- 25

H) 9-(4-Hydroxybutyl)-2-(3,4-dichlorobenzylamino) adenine, HB-DCBA;

I) 9-(2-Carboxyethyl)-2-(3,4-dichlorobenzyl) guanine, CB-DCBG; and

5 J) 9-(2-Aminoethyl)-2-(3,4-dichlorobenzyl)guanine, AE-DCBG.

The compounds of the invention have utility in the treatment of mycoplasma and Gram-positive infections, and have special advantages in the treatment of organisms that
10 have become resistant to currently used therapeutics. They may also be useful in basic identification of organisms which cause infections. The minimal inhibitory concentration (MIC) of 50 μ M or less is desirable for a clinically relevant antibacterial or mycoplasma agent. The
15 MIC may be determined using standard assays and the desirable level of inhibition is as noted above.

The organisms most likely to be treated by the methods of the invention are naturally occurring mycoplasma and Gram-positive bacteria which parasitize humans,
20 livestock or commercially important animals including, but not limited to, pigs, cows, goats, chickens, turkeys, sheep, and laboratory animals (e.g., rats, mice, rabbits). Mycoplasmata and other bacteria which are the targets of the methods of the invention also include those mycoplasmata,
25 etc., which opportunistically infect laboratory or other cultures of eukaryotic (e.g., plant, animal, and insect) cells.

The compounds may be administered both prophylactically and after infection has occurred.
30 Prophylaxis may be most appropriate for immunocompromised animals and human patients and for animals and patients following surgery or dental procedures. This list of relevant conditions for application of the methods of the

invention is not intended to be limiting, and any appropriate infection responsive to the compounds may be treated using the methods and/or compounds of the invention.

Brief Description of the Drawing

5 Fig. 1 is a graph showing analysis of the products of purification step V (Bio-Rex 70 chromatography). Top panel, pol activity in the presence (●) and absence (○) of 200 μ M HPURa. The 3 H cpm represent the level of polymerase activity present in 5 μ l of the indicated fraction. Center
10 panel, SDS-PAGE analysis; 25 μ l of the column input (i) flowthrough (FT), and 25 μ l from the indicated fractions (3-21) were denatured and electrophoresed. The gel was stained with Coomassie brilliant blue, destained, and dried to generate the electrophorogram shown. Bottom panel, display
15 of exo (◆) vs. pol (○) activity; 5 μ l of each fraction was assayed.

Detailed Description

The Gram-positive Pathogens. There are three principle Gram-positive organisms which are amenable to
20 treatment using the new compounds of the invention. Two of these *Staphylococcus aureus* and *Enterococcus fecalis/fecium*, are primarily nosocomial (hospital-acquired) pathogens; together, they presently account for the majority of nosocomial diseases. The third organism is the community-
25 acquired pathogen, *Streptococcus pneumoniae*.

Staphylococcus aureus currently is the most frequent cause of nosocomial bacteremia and skin/wound infection and the second most frequent cause of nosocomial lower respiratory infection. *Enterococcus fecalis/fecium* ranks
30 third behind *Staphylococcus aureus* and *Escherichia coli* as the cause of nosocomial septicemia, endocarditis, and infections of wounds and the urinary tract. *Streptococcus*

pneumoniae causes several serious and potentially life-threatening diseases. In the United States it is estimated that *Streptococcus pneumoniae* accounts annually for 6,000 cases of pneumococcal meningitis, a half million cases of pneumonia, 55,000 cases of bacteremia, and 6 million cases of otitis media. Annual mortality from *Streptococcus pneumoniae*-induced disease is estimated to be 40,000 in the United States and 3-5 million globally.

There presently is a rapidly growing global crisis in the clinical management of life-threatening infectious disease caused by multi-antibiotic-resistant strains of the Gram-positive pathogens *Streptococcus*, *enterococcus*, and *Staphylococcus*. New Gram-positive specific antibiotic targets which can selectively hit these targets must be researched and developed as part of the effort to successfully meet this crisis. Provided herein is a novel class of pol III-selective xenobiotics which have clinical use.

Mycoplasmal Pathogens

Using *Mycoplasma pulmonis* as a model system, we have investigated whether the growth of mycoplasmata are sensitive to Gram-positive selective inhibitors of the HPUra-type.

6-(p-Hydroxyphenylazo)-uracil (HPUra) and a wide variety of structurally related derivatives (all deoxyribonucleotide analogs) are highly selective inhibitors of the replication of Gram-positive bacteria. Their site of action is replicative DNA synthesis, and their specific target within this site is Pol III. These properties of HPUra and its derivatives make them convenient and powerful probes with which to provisionally identify organisms that use Pol

III as their replicative polymerase, and offer a previously unknown method to treat mycoplasmal infections.

Based upon our finding that HPUra derivatives inhibit mycoplasma, we propose that *Mycoplasma* has at least two distinct DNA polymerases; one is the Pol III enzyme. Presumably, all mycoplasmata have a Pol III enzyme. The second class of DNA polymerase in *Mycoplasma* is the ~100 kDa enzyme. Accordingly, previous suggestions that genome reduction during mycoplasmal evolution has resulted in the elimination of all but one DNA polymerase would seem to be incorrect.

Presumably, the newly discovered *M. pulmonis* Pol III is the main DNA "replicase" of *M. pulmonis*. The highly developed functional specialization of the Gram-positive Pol III and the central importance of the enzyme to cell survival seem to have preserved its replicative function during mycoplasmal evolution. Its size and antigenicity (~166 kDa; Fig. 1) is similar to a typical Gram-positive Pol III. The conservation of replicative function is also indicated by the high level of sensitivity of mycoplasmal cell growth and division to the HPUra class of inhibitors. If *M. pulmonis* Pol III were not essential to DNA replication, it is very unlikely that its host would retain significant sensitivity to an inhibitor with the strict degree of Pol III specificity for which HPUra and its derivatives are noted (Brown, 1970, *supra*).


Compounds which may be used to inhibit Mycoplasma

A variety of compounds have been described which affect Gram-positive DNA polymerases. Generally, these compounds function as deoxyribonucleotide analog inhibitors and substrates of DNA polymerases. Examples of such compounds which may be used to inhibit replication of Gram-

positive bacteria and mycoplasmata are pyrimidine or purine derivatives, 2-substituted dATP and N²-substituted dGTP analogs, ribo-, 2'-deoxyribo-, arabino-, 2',3'-dideoxy- or acyclo-nucleotides, N⁶-substituted 6-aminopyrimidines and N²-substituted 2-aminopurines. For characterization of these compounds, see e.g., Wright and Brown, (1990) *Pharmac. Ther.* 47:447-497 (hereby incorporated by reference).

Extensive structure-activity relationship studies have revealed that the 3-position is the only position of the uracil ring that can be substituted without drastic reduction in pol III inhibitory potency (Brown and Wright, *Pharmacology Therapy* 47:447 (1990)). Substituents at this position can actually enhance inhibitor affinity for the polymerase target. For example, 3-alkyl TMAU derivatives (alkyl = Me, Et, n-Pr, n-Bu) are slightly more potent pol III inhibitors than the parent compound (Trantolo et al., *Journal of Medical Chemistry*). Third, as shown in the following table, these alkyl N3 substituents also can increase the antimicrobial potency of TMAU for relevant Gr⁺ organisms, especially antibiotic-resistant strains.


Structure-Activity Relationship for N3-Alkyl
TMAUs vs. Growth of *Staphylococcus aureus* and *B. subtilis*

 X =	Minimal Inhibitory Concentration (μG / ml)		
	Control SA	Methicillin-Resistant SA	Wild-Type BS
H-	8	4	23
CH ₃ -	Not Determined (ND)	ND	7
C ₂ H ₅ -	1	0.5	4
nC ₃ H ₇ -	ND	ND	15
nC ₄ H ₉ -	>>128	0.5	1.8
Methicillin	1	128	ND


Novel Compounds Useful to Inhibit DNA Pol III

Several novel compounds are useful as antibiotics *in vivo* and *in vitro* for the prophylaxis, inhibition, or eradication of pathogenic mycoplasmata. These compounds are primarily 3-substituted uracils and isocytosines, and 9-

The 3- substituted uracils and isocytosines of the invention are of the general formulae:




Uracils




Isocytosines

where R_1 in both uracils and isocytosines is $(CH_2)_nOH$, $CH_2CHOHCH_2OH$, $CH_2CHOHCH_3$, $(CH_2)_mCO_2H$, or $(CH_2)_nNH_2$, n is 2, 3, 4, or 5 and m is 1, 2, 3, or 4; and R_2 is



or




where R_3 and R_4 are H, alkyl, halo, or any other hydrophobic constituents (e.g., CH_3 , C_2H_5 , F, Cl, Br, and $(CH_2)_3$).

Preferred 3-substituted uracil and isocytosine compounds are:


A) 3-(2-Hydroxyethyl)-6-(5-indanylamino)uracil, HE-TMAU;

B) 3-(2-Hydroxyethyl)-6-(5-indanylamino)isocytosine, HE-TMAiC;

- C) 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylanilino)uracil, HE-EMAU;
- D) 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylanilino)isocytosine, HE-EMAIc;
- 5 E) 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino)uracil, HE-DCAU;
- F) 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino)isocytosine, HE-DCAIc;
- G) 3-(4-Hydroxybutyl)-6-(5-indanylamino)uracil, HB-10 TMAU;
- H) 3-(4-Hydroxybutyl)-6-(5-indanylamino)isocytosine, HB-TMAIc;
- I) 3-(Carboxymethyl)-6-(5-indanylamino)uracil, CM-TMAU; and
- 15 J) 3-(Aminoethyl)-6-(5-indanylamino)uracil, AE-TMAU.
- The 9-substituted guanines and adenines of the invention are of the formulae:



Guanines



Adenines

- 20 where R₁ in both guanines and adenines is (CH₂)_nOH, CH₂CHOHCH₂OH, CH₂CHOHCH₃, (CH₂)_mCO₂H, or (CH₂)_nNH₂, n is 2, 3, 4, or 5 and m is 1, 2, 3, or 4; and R₂ is



where R_3 and R_4 are H, alkyl, halo, or any other hydrophobic constituents, e.g., CH_3 , C_2H_5 , F, Cl, Br, and $(\text{CH}_2)_3$.

5 Preferred 9-substituted guanine and adenine compounds are:

- A) 9-(2-Hydroxyethyl)- N^2 -(5-indanyl)guanine, HE-TMPG;
- B) 9-(2-Hydroxyethyl)-2-(5-indanylamino)adenine,
- 10 HE-TMAA;
- C) 9-(2-Hydroxyethyl)- N^2 -(3-ethyl-4-methylphenyl)guanine, HE-EMPG;
- D) 9-(2-Hydroxyethyl)-2-(3-ethyl-4-methylanilino)adenine, HE-EMAA;
- 15 E) 9-(2-Hydroxyethyl)- N^2 -(3,4-dichlorobenzyl)guanine, HE-DCBG;
- F) 9-(2-Hydroxyethyl)-2-(3,4-dichlorobenzylamino)adenine, HE-DCBA;
- G) 9-(4-Hydroxybutyl)- N^2 -(3,4-dichlorobenzyl)
- 20 guanine, HB-DCBG;
- H) 9-(4-Hydroxybutyl)-2-(3,4-dichlorobenzylamino)adenine, HB-DCBA;
- I) 9-(2-Carboxyethyl)-2-(3,4-dichlorobenzyl)guanine, CE-DCBG; and
- 25 J) 9-(2-Aminoethyl)-2-(3,4-dichlorobenzyl)guanine, AE-DCBG.

Therapeutic Administration of Compounds

The compounds herein before described are useful for the treatment of bacterial infections in humans caused by Gram positive bacteria, including strains resistant to
5 common antibiotic drugs. The compounds are also useful for treatment of mycoplasma infections in humans caused by various species of the genera *Mycoplasma* and *Ureaplasma*. They are also useful for treatment of related Gram-positive bacterial infections and mycoplasmata infections in animals,
10 and for eliminating or avoiding mycoplasmal infections of eukaryotic cell cultures.

The compounds of the invention can be formulated for pharmaceutical, veterinary, and tissue culture use, optionally together with an acceptable diluent, carrier or
15 excipient and/or in unit dosage form. In using the compounds of the invention, conventional pharmaceutical, veterinary, or culture practice may be employed to provide suitable formulations or compositions.

Thus, for human or animal use, the formulations of
20 this invention can be administered by parenteral administration, for example, intravenous, subcutaneous, intramuscular, intraorbital, ophthalmic, intraventricular, intracranial, intracapsular, intraspinal, intracisternal, intraperitoneal, topical, intranasal, aerosol,
25 scarification, and also oral, buccal, rectal, vaginal, or topical administration.

The formulations of this invention may also be administered by the use of surgical implants which release the compounds of the invention.

30 Parenteral formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; and

for intranasal formulations, in the form of powders, nasal drops, or aerosols.

Methods well known in the art for making formulations can be found in, for example, "Remington's
5 Pharmaceutical Sciences." Formulations for parenteral administration may, for example, contain as excipients sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes, biocompatible, biodegradable
10 lactide polymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the present factors. Other potentially useful parenteral delivery systems for the factors include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion
15 systems, and liposomes. Formulations for inhalation may contain as excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in
20 the form of nasal drops, or as a gel to be applied intranasally. Formulations for parenteral administration may also include glycocholate for buccal administration, methoxysalicylate for rectal administration, or citric acid for vaginal administration.

25 The concentration of the compound in the formulations of the invention will vary depending upon a number of factors, including the dosage to be administered, and the route of administration.

In general terms, the compounds of the invention may
30 be provided in an aqueous physiological buffer solution containing about 0.1 to 10% w/v compound for parenteral administration. General dose ranges are from about 0.01 mg/kg to about 1 g/kg of body weight per day; a preferred

dose range is from about 0.01 mg/kg to 100 mg/kg of body weight per day. The preferred dosage to be administered is likely to depend upon the type and extent of progression of the infection being addressed, the overall health of the patient, and the route of administration. For topical and oral administration, formulations and dosages can be similar to those used for other antibiotic drugs, e.g., erythromycin.

10 Detection of Mycoplasma Infection and Evaluation of Efficacy/Toxicity of Compounds

Detection of Infection

Many standard methods of detecting mycoplasmata infection exist and may be used for both *in vitro* and *in vivo* use. The examples provided here are not intended to be limiting. Detection of Gram-positive bacterial infection may be carried out by any standard method (e.g., Gram staining).

A preferred method to detect mycoplasmal infection both *in vitro* and *in vivo* is the use of the polymerase chain reaction (PCR). This method can be used for both qualitative and quantitative evaluation of infection. Primers are selected from unique regions of the genome which are not conserved between *Mycoplasma* and Gram-positive bacteria, and reaction conditions are determined as is standard in the art (see e.g., Ochman et al. in PCR Protocols: A Guide to Methods and Applications, Academic Press: San Diego (1990)). The presence of an amplified cDNA of the correct size is indicative of mycoplasmal infection. The cDNA may be sequenced for verification of mycoplasmal identity. Such primers are also useful for quantitative PCR (e.g., to determine efficacy of a compound to inhibit mycoplasma replication) using fewer amplification cycles.

Appropriate protocols may be found in Ochman et al., *supra*. Samples for amplification may be obtained from cell cultures, or tissue or blood samples from animals or humans.

Evaluation of Efficacy of Antibiotic Compounds

5 The mycoplasmal inhibiting properties of novel and previously known compounds useful in the methods of the invention may be tested using the simple assay described in the Experimental Procedures below. Briefly, using standard mycoplasmal growth conditions on agar plates with or without
10 supplementation by test compounds, growth inhibition at various concentrations can be evaluated for any test compound. Alternatively, the test compound may be applied to liquid cultures at varying concentrations and growth inhibition monitored. Growth inhibition, i.e. of cell
15 replication, by plate, a MIC of 50 μ m or less; in liquid medium, inhibition of 90% at 100 μ m or less.

 A direct method to assay for a test compound's ability to inhibit the activity of DNA Pol III is by using a DNA polymerase assay as described (Barnes and Brown Nuc. Acids Res., 6:1203-19 (1979); Trantolo et al. (1986) J. Med. Chem. 29:676-681; Mills et al., J. Bacteriol., 132:641-49 (1977); and Low et al., J. Biol. Chem., 251:1311-25 (1976); all hereby incorporated by reference). This rapid screening method can use natural or recombinant DNA pol III enzyme in
25 a standard DNA polymerase activity assay. There are numerous methods for such assays known in the art (see above references, for example). By including a test compound in a side-by-side assay with a control, the effect of the test compound on polymerase activity can be assessed. Test
30 compounds with an appropriate level of inhibition of the natural or recombinant mycoplasmal DNA polymerase III are good candidate therapeutics for further evaluation.

Evaluation of Toxicity

Toxicity of the novel compounds described above will be evaluated according to standard methods known to those skilled in that art (see Gootz, T.D. (1990) Clin. Microbiol. Rev., 3, 13-31). Determination of the toxic dose (or "LD₅₀") can be carried out as described in the Experimental procedures or using other protocols well known in the field of pharmacology, and a suitable range of IC₅₀ values for a compound to be considered for further therapeutic evaluation will be on the order of the MIC or IC₅₀ in cultures, i.e., the therapeutic index should be greater than 10.

Experimental procedures

Mycoplasmal growth and drug inhibition

M. pulmonis strain KD735-15 (construction described in Bhugra and Dybvig, 1992) was propagated in mycoplasmal medium, and colony-forming units (cfu) were assessed on agar as previously described (Dybvig and Cassell, 1987). *M. pulmonis* is a representative species which is well characterized. Other publicly available strains may also be used. For example, *Mycoplasma agalactiae*, ATCC 35890, *Mycoplasma arthritidis* ATCC 13988, *Mycoplasma bovirhinalium*, ATCC 14173, *Mycoplasma bovirhinalis*, ATCC 27748, *Mycoplasma bovis*, ATCC 25025, *Mycoplasma felis*, ATCC 23391, *Mycoplasma gallinaceum*, ATCC 33550, *Mycoplasma gallinarum*, ATCC 15319, *Mycoplasma gallisepticum*, ATCC 15302, *Mycoplasma genitalium*, ATCC 33530, *Mycoplasma hominis*, ATCC 14027, *Mycoplasma hyorhinalis*, ATCC 17981, *Mycoplasma hyosynoviae*, ATCC 25591, *Mycoplasma meleagridis*, ATCC 25294, *Mycoplasma orale*, ATCC 15539, *Mycoplasma pneumoniae*, ATCC 15293, *Mycoplasma pullorum*, ATCC 33553, *Mycoplasma pulmonis*, ATCC 14267, *Mycoplasma putrefaciens*,

ATCC 15718, *Mycoplasma synoviae*, ATCC 25204, may also be used. The inhibitors used here were prepared as described in Wright and Brown ((1990) *Pharmac. Ther.* 47:447-497) and were prepared at a stock concentration of 20 mM in dimethyl sulphoxide (DMSO). Growth inhibition was examined on agar by comparing cfu obtained on medium lacking or supplemented with antibiotic. DMSO alone at concentrations as high as 1% had no effect on growth or cfu capacity of *M. pulmonis*.

10 Enzyme purification

General methods for purification and identification of DNA polymerase III from gram-positive bacteria are known in the art. Provided here is the protocol for isolation of a 5 L culture of *M. pulmonis* was grown to mid-log phase and rapidly cooled to 4°C. The cells were harvested by centrifugation at 4°C and washed twice by recentrifugation from ice-cold, phosphate-buffered saline (150 mM BaCl:10 mM potassium phosphate, pH 7.6). The packed cells (~3.5 g) were rapidly frozen as 0.7 g pellets in a dry ice-ethanol bath and stored at -80°C. The following procedure, summarized in Table 1, applies to the purification of a single 0.7 g pellet.

Fraction I (Crude extract): All procedures were carried out at 4°C, and the protein concentration of fractions was determined by the method of Bradford (Anal. Biochem., 72:248-54 (1976)), using a bovine serum albumin standard. A single cell pellet was resuspended in 1 ml of column buffer (50 mM potassium phosphate, pH 7.5; 1 mM PMSF). The cells were disrupted in a French pressure cell at approximately 138,000 kPa and centrifuged at 20,000 x g for 60 min to generate a clear supernatant (Fraction I).

Fraction II (ammonium sulphate precipitation):
Fraction I was mixed with three volumes of a saturated

solution of ammonium sulphate in 50 mM Tris-HCl (pH 8.0):2 mM DTT. The resulting cloudy suspension was stirred for 1 h and centrifuged at 20,000 x g for 20 min. The pellet was dissolved in 3 ml of column buffer containing 1.5 M NaCl, and the resultant solution was clarified by centrifugation to yield Fraction II.

Fraction III (phenyl sepharose eluate): Fraction II was applied to a 1 ml phenyl sepharose (Sigma Chemical Corp.) column equilibrated in column buffer containing 1.5 M NaCl. The column was washed with 2 vol. of the same buffer and subsequently with 1.1 vol. of column buffer. The column was eluted with 3 vol. of column buffer containing 1% Triton X-100 to generate Fraction III.

Fraction IV (macro-prep high econo Q chromatography): Fraction III was applied to a 2 ml column of macro-prep high-capacity econo Q (Bio-Rad) equilibrated with column buffer containing 1% Triton X-100. The column was then washed with approximately 10 ml of the same buffer, and eluted with a 40 ml gradient of 0-0.2 M NaCl (also based in the same buffer). A broad peak of DNA polymerase activity eluted at approximately 0.08 M NaCl, and the active fractions were pooled to generate Fraction IV.

Fraction Va (Bio-Rex 70 chromatography): Fraction IV was diluted with column buffer containing 1% Triton X-100 to reduce the concentration of NaCl to 25 mM, and then applied to a 2 ml Bio-Rex 70 (Bio-Rad) column equilibrated in column buffer containing 1% Triton X-100 + 25 mM NaCl. The column was washed with 5 ml of the same buffer, and the adsorbed enzyme was eluted in two distinct peaks (designated A and B) at approximately 0.15 and 0.30 M NaCl, respectively. The chromatogram is summarized in Fig. 1. As the top panel of the figure indicates, peak A represents the

HPUra-sensitive pol activity. Peak A was pooled to generate Fraction Va.

Enzyme assays and determination of inhibitor IC₅₀ values

DNA pol activity was assayed as described (Barnes et al., Nuc. Acids Res., 6:1203-19 (1979)), using activated calf-thymus DNA as template primer, 10 pM [³H-methyl]-dTTP as the labelled dNTP substrate, and dATP, dCTP, and dGTP at 25 μM each. For determination of IC₅₀ values of TMAU and the four arylazopyrimidines (summarized in Table 2), the concentration of dGTP was reduced from 25 to 10 μM. TMAU was used directly in enzyme assays, and arylazopyrimidines were reduced prior to assay to the active, hydrazino forms, using sodium dithionite as described by Wright and Brown (1977) *J. Med. Chem.* 20:1181-1185.

Exo activity was assayed as described by Löw et al. (1976), *supra*, using denatured calf-thymus DNA incorporating [³H]-dTTP residues at the 3'-OH ends.

SDS-PAGE and immunoblot analysis of Bio-Rex fractions

SDS-PAGE exploited the method of Laemmli (1970) and employed 1.5 mm x 83 mm x 102 mm, 15-well gels containing 7.5% polyacrylamide (Bio-Rad) and 0.2% bis-acrylamide (Bio-Rad). For immunoblot analysis, 25 μl samples of selected Bio-Rex chromatographic fractions or other control fractions of interest were denatured (Laemmli, 1970) and subjected to SDS-PAGE. Gels were blotted to nylon-reinforced nitrocellulose membranes (Nitro Plus 2000, Micron Separations, Inc.) and subjected to the following immunoblot analysis based on the method of Towbin et al., Proc. Natl. Acad. Sci. USA, 76:4350-54 (1979). The blots were exposed to primary antibody (rabbit polyclonal anti-Pol III IgG;

(Barnes et al., (1979) *supra*) at a concentration of 2.5 $\mu\text{g ml}^{-1}$. The secondary antibody (biotinylated goat anti-rabbit IgG; Sigma) was used at a concentration of 5 $\mu\text{g ml}^{-1}$. Following treatment with the second antibody the blots were
5 stained with streptavidin-linked horseradish peroxidase (Sigma; 5 $\mu\text{g ml}^{-1}$), rinsed, and developed with H_2O_2 /o-dianisidine.

The following examples are intended to illustrate the invention and are not intended to be limiting.

10

EXAMPLES

Example 1: Inhibition of mycoplasmal growth with antimicrobials of the HPUra Type

HPUra and 25 other agents selected from a large collection of structurally related compounds (Wright and
15 Brown, 1990, *Pharmac. Ther.* 47:447-497) were tested against *M. pulmonis* at a concentration of 200 μM as described in the Experimental procedures. HPUra and 15 others completely inhibited colony formation. Of these, HPUra and three
20 others (6-(phenylazo)uracil (PUra), 6-(p-chlorophenylazo)uracil (PCPUra), and 6-(m-chlorophenylazo)uracil (MCPUra)) were compared with respect to potency in a series of decreasing concentrations (100, 50, 25, 12.5 and 6.25 μM). The concentration of each agent that was required to inhibit colony formation by 99% was as follows: PCPUra < 6.25 μM ;
25 PUra, 6.25-12.5 μM ; MCPUra, 12.5 μM ; and HPUra, 12.5-2.5 μM . Thus these agents displayed a level of potency against *M. pulmonis* that was fully equivalent to that displayed against low-GC Gram-positive bacteria such as *B. subtilis*, *Enterococcus faecalis*, and *Staphylococcus aureus* (Barnes et
30 al., (1979) *supra*).

Example 2: Isolation of a DNA polymerase activity from *M. pulmonis* similar to that of a Gram-positive Pol III

The sensitivity of the growth of *M. pulmonis* to HPURa and its close derivatives indicated that the organism carried an appropriate enzyme target. To explore this suggestion, we prepared a crude extract of *M. pulmonis* (Fraction 1 as defined in the Experimental procedures) and examined it for the presence of a polymerase activity which was sensitive to HPURa and similar agents. The extract displayed a level of pol activity that would be expected for a low-GC Gram-positive organism, and a significant portion of this activity (~50%) was HPURa sensitive (results not shown).

To characterize the HPURa-sensitive pol activity further, we purified it using a five-step scheme summarized in Table 1 and described in the Experimental procedures. Fig. 1 summarizes an analysis of the Bio-Rex 70 chromatogram of pol activity developed in step V, the final step of the procedure. As the activity curve (open circle symbols) of the top panel indicates, Bio-Rex chromatography resolved two peaks of pol activity, A and B. Re-assay of the fractions in the presence of 200 μ M HPURa (filled circle symbols) indicated that the pol activity represented by peak A was drug-sensitive, while that of peak B was insensitive.

TABLE 1
Summary of Pol III Purification

FRACTION	UNITS ¹	mg PROTEIN	SPECIFIC ACTIVITY (UNITS mg ⁻¹)
I. Crude extract	7.8	28	0.28
5 II. Ammonium sulphate ppt.	30.9 ²	25	1.2
III. Phenyl sepharose	37.5	7.2	5.2
IV. Econo Q	25.7	0.83	31
V. Bio-Rex 70	7.4	0.11	65

10 1 One unit is equal to the amount of TMAU-sensitive enzyme required to catalyze the incorporation of 1 nmole [³H]-dTMP into acid-precipitable material in 10 min under the assay conditions.

2 The apparent increase in the activity at this step results from the removal of an inhibitory substance.

To determine if the pol activity in peak A was
15 similar to a Gram-positive-specific Pol III, we evaluated whether a) the activity display the appropriate level of sensitivity as representative Gram-positive Pol III-specific inhibitors; b) the activity was associated with a polypeptide of a similar size (i.e., ~160 kDa); and c) the
20 activity was associated physically with an exo activity. The results of these inquiries are described below.

a) Sensitivity of peak A pol activity to HPURa-type inhibitors

Five compounds were used to assess the sensitivity
25 of peak A pol activity to HPURa-type inhibitors. These were the four compounds used in the growth experiment described above (HPURa, PURa, PCPURa, and MCPURa) as well as TMAU (6-(3', 4'-trimethylanilino) uracil), a 'second generation' derivative of the HPURa prototype, equivalent in mechanism
30 and target specificity (Wright and Brown, 1990). The IC₅₀

value (the concentration required for 50% inhibition) of each of these agents was determined for the peak A pol activity and for an inhibitor-sensitive control enzyme, *B. subtilis* Pol III. The results, summarized in Table 2, indicated that the peak A polymerase typified a Gram-positive-specific Pol III with respect to inhibitor sensitivity.

TABLE 2

Inhibitor Sensitivity of *B. subtilis* and *M. pulmonis* DNA polymerases

IC₅₀³

	<i>B. subtilis</i> ⁴	<i>M. pulmonis</i> ⁵
HPUra	11	14
PUra	34	20
MCPUra	48	17
PCPUra	57	31
TMAU	8	11

³ Concentration (μ M) required for 50% inhibition of polymerase activity; assay conditions are defined in the Experimental procedures.

⁴ *B. subtilis* Pol III was prepared and used as described by (Barnes et al., (1979) *supra*).

⁵ Fraction 7 from peak A, Bio-Rex 70 chromatogram of Fig. 1.

b) Identification of a ~166 kDa polypeptide associated with peak A pol activity

SDS-PAGE was used to examine whether a Pol III-specific polypeptide of ~160 kDa was associated with peak A. The middle panel of Fig. 1 displays the SDS-PAGE analysis of samples of relevant fractions of the chromatogram shown in the top panel. It indicates the coincidental elution, in fractions 6-9, of the catalytic activities of peak A and a polypeptide of ~166 kDa (noted by an arrow on the y-axis),

the size expected for a typical Gram-positive-specific Pol III.

To determine if the latter peptide was, in fact, Pol III, we subjected the peak fraction (no. 7) of peak A and, as a control, the peak fraction (no. 15) of peak B to SDS-PAGE/immunoblot analysis. The analysis exploited a polyclonal antibody raised against the 162.4 kDa *B. subtilis* Pol III. This reagent reacts strongly and specifically not only with blotted *B. subtilis* Pol III, but also with those of several other Gram-positive organisms such as *Staphylococcus* and *Streptococcus* (Barnes et al., (1979) *supra*). The results of the analysis, which are not shown, clearly indicated that the ~166 kDa polypeptide band of peak A was strongly reactive for the antibody and was the only gel band of either peak that specifically reacted with the antibody probe.

c) *Physical association of the peak A pol activity with exo activity*

The fractions of the chromatogram shown in the top panel of Fig. 1 were analyzed for exo activity. These results and those of the previous pol assay were plotted to generate the composite activity profile of the lower panel of Fig. 1. The profile indicates a single sharp peak of exo activity (filled diamond symbols) perfectly coincident with the peak of HPURa-sensitive pol activity (open circle symbols; peak A). Although the pol-exo coincidence was consistent with what would be expected for a typical Gram-positive-specific Pol III polypeptide, it was nevertheless possible that the exo activity was associated with an unrelated protein which fortuitously co-chromatographed with the HPURa-sensitive pol activity.

To determine if the pol-exo functions were separate or physically associated, we took advantage of two basic properties of the mechanism of interaction of Gram-positive Pol IIIs and agents of the HPURA class. One is the inherent inhibitor resistance of its exo activity in the presence of a single-stranded (ss) DNA substrate, and the other is the physical sequestration of enzyme which forms the basis of agent-induced pol inhibition in the presence of double-stranded (ds) DNA. These two properties and the experiment that exploited them are explained briefly below.

Sequestration:

Although formally pyrimidines, inhibitors of the HPURA class incorporate a novel base-pairing domain which endows them with the capacity to specifically mimic the purine dNTP, dGTP, and compete with its binding to template cytosine. The capacity of these agents to inhibit the pol activity of their target - a capacity which can be specifically and competitively antagonized by dGTP - is strictly dependent on the provision of a specific primer-template structure in the pol reaction. The template must be H-bonded to a 3'-OH-terminated primer, and must contain the inhibitor complement, cytosine, and present it as the first unpaired residue proximal to the primer terminus. When provided with this dsDNA structure, the inhibitor inserts its aryl substituent into the enzyme's dNTP-binding site and simultaneously forms three H bonds with the unopposed template cytosine. As a result, the enzyme becomes firmly sequestered to the DNA in a catalytically inactive, protein-inhibitor-template primer complex. As expected, dGTP specifically competes with the inhibitor to antagonize the formation of this complex.

Inhibitor-resistant exo activity on ssDNA:

Because the Gram-positive-specific Pol III is a primer-driven enzyme, its pol site cannot utilize ssDNA to catalyze dNTP polymerization. In contrast, the enzyme's exo site prefers ssDNA, binding and digesting it at least 100 times more efficiently than dsDNA. If a polymerase molecule is exposed to an HPURa-type inhibitor while its exo site is digesting ssDNA, essentially no inhibition is observed. However, when the same reaction is first supplemented with an appropriate ds template primer, it is strongly inhibited upon exposure to the drug. The basis for the sensitizing effect of the dsDNA is simply its capacity to foster inhibitor-induced enzyme sequestration, a process that physically entraps the enzyme protein and prevents its exo site from acting on ssDNA. As expected from consideration of mechanism, dGTP specifically antagonizes this sequestration-induced inhibition.

Example 3: Effects of HPURa and structurally related compounds on exo activity

Preliminary experiments, the results of which are not shown, indicated that the activity of the peak A exo on ssDNA was resistant to TMAU at 50 μ M, a concentration at least 50 times that of its 'pol' K_i on *B. subtilis* Pol III (Wright and Brown, 1977). Given this result, we further examined whether the exo activity of the peak A enzyme on ssDNA becomes susceptible to TMAU-induced sequestration when the reaction is supplemented with double stranded primer template, and if so, if the susceptibility is selectively antagonized by dGTP, the specific competitor of inhibitor-induced sequestration.

The results of the experiment are summarized in Table 3. TMAU at 50 μ M inhibited ssDNA digestion by about 70% in the presence of dsDNA. When the latter mixture was supplemented with 500 μ M dGTP, the specific antagonist of TMAU-induced sequestration inhibition was reduced to a level of <3%. In contrast, the same concentration dATP, a 'control' dNTP without effect on TMAU-induced sequestration, had no significant effect on the level of inhibition. Together, these results indicated that the exo and pol activities are strongly associated in an inhibitor-sequestrable unit similar to a Gram-positive-specific Pol III.

TABLE 3
Sequestration of the exo activity of peak A pol by TMAU

15	Addition	Activity ⁶ (%)		
20	TMAU	dATP	dGTP	
	(50 μM)	(500 μM)	(500 μM)	
	-	-	-	100
	-	+	-	101
	-	-	+	103
	+	-	-	31
	+	+	-	31
	+	-	+	98

6 Exo activity was assayed on 3'-([³H])-thymidine)-labelled ssDNA under 'sequestering' conditions in the presence of dsDNA as described in the Experimental procedures 100% activity is equivalent to the release of - 6000 c.p.m. (of 16,000 acid-precipitable c.p.m. per assay).


Example 4: Organic Synthesis of Compounds of the Invention

The following is an example of a method of synthesis of 1-substituted uracil and isocytosine compounds. This example is not intended to be limiting.

Example 4a:

5

Preferred compounds are HE-TMAU and HE-TMAiC. Synthesis follows generally the method in Nogimori et al., J. Med. Chem. (1985) 28:1692-1694.



Steps of Synthesis

6-(5-Indanylamino)-2-thiouracil (a). 6-Amino-2-thiouracil is heated for 4 hours at 160°C with an equimolar mixture of 5-aminoindan and the hydrochloride of 5-aminoindan. The product is crystallized from ethanol/water and isolated in 5 66% yield, mp 269-272°C.

2-Methylmercapto-6-(5-indanylamino)-4-pyrimidone (b). Compound a is dissolved in ethanolic potassium hydroxide, and the solution is treated with methyl iodide at rt. After stirring for one hour, the solution is evaporated and the 10 residue crystallized from ethanol. The product is isolated in 89% yield, mp 235-238°C.

1- and 3-(2-Acetoxyethyl)-2-methylmercapto-6-(5-indanylamino)-4-pyrimidones, (c and d). Compound b is dissolved in ethanolic potassium hydroxide and the solvent 15 is evaporated. Dry N,N-dimethylformamide is added, and the solution is cooled to 4°C. 2-Acetoxyethyl bromide is added and the mixture is stirred at 4°C for 3 days. Evaporation of the solvent and chromatography of the residue on silica gel separates compounds c and d in ca. 3:1 ratio. The 20 isomers are identified by characteristic ¹H NMR signals [Nogimori et al., 1985].

3-(2-Hydroxyethyl)-6-(5-indanylamino)uracil, HE-TMAU (e). Compound d is heated at reflux in a mixture of conc. hydrochloric acid and methanol for one hour. The residue 25 after evaporation of solvents is crystallized from aqueous ethanol.


3-(2-Hydroxyethyl)-6-(5-indanylamino)isocytosine, HE-TMAiC (f). Compound d is heated in a sealed bomb with ammonia-saturated methanol at 120°C for 2 hours. The

residue after evaporation of solvent is crystallized from water.

Example 4b:

The following is an example of a method of synthesis of 9-substituted guanine and adenine compounds. This example is not intended to be limiting.

Preferred compounds are HB-DCBG and HB-DCBA. Synthesis generally follows the procedure of Xu et al. (ms. submitted):



The general procedure for synthesizing 9-substituted guanines is as follows:

- a) 2-Bromohypoxanthine and 3,4-dichlorobenzylamine are heated at reflux in 2-methoxyethanol as described (Wright and Dudycz, J. Med. Chem., 27:175 (1984)). N²-(3,4-Dichlorobenzyl) guanine (DCBG) is obtained in 83% yield.
- b) DCBG is heated with thionyl chloride in dimethyl-formamide for 1h. Crystallization from ethanol gives 84% of 2-(3,4-dichlorobenzylamino)-6-chloropurine.
- 10 c) Sodium hydride (60% suspension in mineral oil) is added in an equimolar amount to a suspension of 2-(3,4-dichlorobenzylamino)-6-chloropurine (0.35 g/100 ml) in anhydrous acetonitrile at room temperature (rt). After stirring for 1 hr, the appropriate 4-acetoxybutyl bromide (1
15 eq.) is added, and the suspension is stirred for 48 hrs at rt. An equal volume of chloroform is added, and after filtration through Celite, the filtrate is evaporated to dryness. The residue is chromatographed on silica gel (230-400 mesh) and the products are eluted with chloroform to
20 give the major 2-(3,4-dichlorobenzyl-amino-6-chloro-9-(4-acetoxybutyl) purine and then the minor 7 isomer.
- d) A suspension of the 9-isomer from above in 0.5 N sodium hydroxide solution is heated at reflux for 2 hr. After neutralization with 0.5 N hydrochloric acid, the
25 solution is placed in the refrigerator overnight. The colorless solid is collected and crystallized from dimethylformamide (HB-DCBG).
- e) A mixture of the 9 isomer from step c) is heated in a sealed bomb with ammonia-saturated methanol at 120°C
30 for 5 hours. Crystallization of crude product from methanol affords HB-DCBA.

The examples provided above are meant to illustrate the synthesis and characterization of a representative subset of the compounds of the invention. Analogous methods known to one skilled in the art can be used for the

5 synthesis and characterization of other compounds of the invention (see, "Advanced Organic Chemistry," J. March, 3rd. ed., NY: John Wiley, 1985; "The Chemistry of Functional Groups," S. Patai, Ed., NY: John Wiley, multiple volumes, 1960ff; Heterocyclic and nucleoside synthesis - "Purines,"

10 J.H. Lister, NY: Wiley-Interscience, 1971; "Chemistry of Nucleosides and Nucleotides," Vols 1 and 2, L.B. Townsend, Ed., NY: Plenum Press, 1988; Medicinal chemistry - "The Basis of Medicinal Chemistry," 4th ed., 3 vols., M.E. Wolff, Ed., NY: Wiley-Interscience, 1980, all incorporated herein

15 by reference).

EXAMPLE 5: Detection of mycoplasmata in vivo and in vitro

A protocol which is useful for identifying mycoplasmal infection in cultured cells or cells placed in primary culture from human or animals is a DNA labelling

20 method, which may be conducted as follows.

In situ DNA fluorescence is a very efficient method of screening for mycoplasma contamination in cell cultures. Bisbenzimidazole (Hoechst 33258) and DAPI (4', 6-Diamidino-2-phenylindole) are DNA fluorochromes which bind specifically

25 to the Adenine-Thymidine (A-T) regions of DNA. Cultures contaminated with mycoplasma will have small, uniformly shaped fluorescent bodies evident in the extranuclear and intracellular spaces. Nuclei of cultured cells will also fluoresce.

30 Artifacts may fluoresce and interfere with interpretation. They will appear larger in size than

mycoplasma and irregular in shape. Using healthy, log-phase indicator cells and test cells will reduce interference caused by artifacts.

Materials

- 5 Indicator cells, Vero (ATCC®CCL 81) or 3T6-Swiss albino (ATCC CCL 96)
- Leighton tubes or glass cover slips/culture dishes
- Cell culture medium (growth medium)
- Methanol
- 10 Glacial acetic acid
- Bisbenzimidazole or DAPI
- Mounting Solution McIlvaine's Buffer: Glycerol [1:1]
- Fluorescent microscope

Procedure

- 15 *Culturing samples and indicator cells*
 - 1. Seed indicator cells at low density in a Leighton tube or on a glass coverslip in a culture dish containing tissue culture medium. Incubate for 24 hours at the conditions appropriate for the culture medium (typically
 - 20 37°C at 5% or 2% CO₂). Prepare enough cultures to inoculate with control and test samples.
 - 2. To separate indicator cell cultures, add 0.1 ml of test samples. *Negative control:* Indicator cell cultures inoculated with 0.1 ml of culture medium. *Positive control:*
 - 25 If a positive control is desired, infect a culture of the indicator cells with 0.1 ml of a viable culture of mycoplasma species.
 - 3. Allow all cultures to incubate for an additional 4 days.

NOTE: It is important to stain and examine cultures before they reach confluency. Adjust incubation time and inoculum density according to the growth characteristics of the test and indicator cells.

5 *Fixing Cells*

1. Prepare Carnoy's fixative fresh on the day of use. Solution consists of 3 parts methanol to 1 part glacial acetic acid. Prepare enough solution to fix all cultures. Approximately 15 ml of fixative is required per culture.
2. Without decanting growth medium, add approximately 5 ml of Carnoy's fixative to each culture and allow to stand 2 minutes.
3. Decant and add 5 ml of fixative to the cultures and allow to stand 5 minutes.
4. Decant fixative, add 5 ml of fresh fixative, and allow to stand 5 minutes.
5. Finally, decant fixative and allow growth surface to air dry approximately 5 minutes.

20 *Staining and Mounting Cells*

1. Prepare working concentrations of fluorochrome stain (Bisbenzimidazole) by dissolving 0.25-0.5 mg/ml of distilled water. Concentration of stock solution should be 50 mg/ml and stored in the dark. Stock solution should be sterile and discarded if performance deteriorates. Note: DAPI may be substituted for bisbenzimidazole. Solubilize DAPI in Phosphate Buffered Saline (PBS) at 0.1 mg/ml. Stain cells for 15-30 minutes.
2. Completely immerse the growth surface in the stain solution and allow to stand for 30 minutes.
3. Rinse twice with distilled water.

4. Mount growth surface, cell side down, with a drop of mounting solution on a microscope slide. Slides may be preserved by sealing the edges of the cover slip and slide with clear nail polish. Slides should be protected
5 from light and heat. These will last several weeks without quenching if properly stored.

Examining Cultures

A fluorescent microscope capable of epifluorescence is needed for visualizing the stain preparations. A typical
10 system includes fluorescent microscope with a 53/44 barrier filter and a BG-3 exciter filter. A total magnification of 500X (40X;12.5) is usually sufficient to visualize mycoplasma but higher magnification may be used. These methods are derived from (Chen, Exp. Cell Res., 104:255-62
15 (1977); Hay et al., Nature, 339:387-88 (1989); and McGarrity et al., In: Methods in mycoplasmaology, Tully and Razin (eds), 2:487-88 (1983).

Uses/Advantages of the Invention

The compounds of this invention are inhibitors of
20 the DNA polymerase III enzymes from Gram-positive bacteria, specifically, pathogenic Enterococci, streptococci, staphylococci, and strains thereof resistant to currently used antibiotics and are also inhibitors including mycoplasmata of the genera *Mycoplasma* and *Spiroplasma* and
25 *Ureaplasma*. Inhibition of DNA polymerase III, the enzyme responsible for replication of the genome of the organism, causes inhibition of growth of the organism. The derivatives contain hydroxyalkyl, aminoalkyl or carboxyalkyl groups that increase water solubility of the compounds,
30 facilitating their absorption and distribution in humans and

animals, without interfering with their inhibition of growth of gram positive bacteria and mycoplasma spp.


The compounds of the invention can be used as screening tools to provisionally identify the DNA replicase
5 'phenotype' of an organism and, beyond that, as refined genetic and physical probes with which to dissect the machinery of mycoplasma DNA metabolism.

The low toxicity of HPURa and its close derivatives in mammalian cells (Brown et al., 1986, *supra*) also endows
10 this class of agents with the characteristics required of Gram-positive- and mycoplasma-specific therapeutic antimicrobials. For example, they may be applicable in the clinic as chemotherapeutic agents capable of circumventing the natural and acquired resistance of pathogenic
15 mycoplasmata to conventional antimicrobials.

What is claimed is:

1 1. A method of inhibiting mycoplasma cells, said
2 method comprising contacting said cell with an effective
3 amount of a HPURa-like compound.

1 2. A method of inhibiting a cell which is either a
2 Gram-positive bacterial cell or a mycoplasma cell, said
3 method comprising contacting said cell with an effective
4 amount of a compound chosen from the group consisting of



7 wherein R₁ is (CH₂)_nOH, CH₂CHOHCH₂OH, CH₂CHOHCH₃,
8 (CH₂)_mCO₂H, or (CH₂)_nNH₂, n is 2, 3, 4, or 5 and m is 1, 2, 3,
9 or 4; and R₂ is



12 where R₃ and R₄ are H, alkyl, halo, or any other
13 hydrophobic constituents.

1 3. The method of claim 1 or 2 wherein said
2 inhibiting is in an animal.

- 1 4. The method of claim 3 wherein said animal is a
2 human.
- 1 5. The method of claim 1 or 2 wherein said
2 inhibiting is in an *in vitro* culture of eukaryotic cells.
- 1 6. The method of claim 1 wherein said inhibiting is
2 to prevent a mycoplasma infection.
- 1 7. The method of claim 2 wherein said inhibiting is
2 to prevent a gram-positive bacterial infection.
- 1 8. The method of claim 2 wherein said compound is
2 3-(2-Hydroxyethyl)-6-(5-indanylamino)uracil (HB-TMAU).
- 1 9. The method of claim 2 wherein said compound is
2 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylanilino)uracil (HE-
3 EMAU).
- 1 10. The method of claim 2 wherein said compound is
2 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino)- uracil (HE-
3 DCAU).
- 1 11. The method of claim 2 wherein said compound is
2 3-(4-Hydroxybutyl)-6-(5-indanylamino)uracil (HB-TMAU).
- 1 12. The method of claim 2 wherein said compound is
2 3-(Carboxymethyl)-6-(5-indanylamino)uracil (CM-TMAU).
- 1 13. The method of claim 2 wherein said compound is
2 3-(Aminoethyl)-6-(5-indanylamino)uracil (AE-TMAU).

1 14. The method of claim 2 wherein said compound is
2 3-(2-Hydroxyethyl)-6-(5-indanylamino)- isocytosine (HE-
3 TMAiC).

1 15. The method of claim 2 wherein said compound is
2 3-(2-Hydroxyethyl)-6-(3-ethyl-4-methylanilino)- isocytosine
3 (HE-EMAiC).

1 16. The method of claim 2 wherein said compound is
2 3-(2-Hydroxyethyl)-6-(3,4-dichlorobenzylamino)- isocytosine
3 (HE-DCAiC).

1 17. The method of claim 2 wherein said compound is
2 3-(4-Hydroxybutyl)-6-(5-indanylamino)- isocytosine (HB-
3 TMAiC).

1 18. The method of claim 2 wherein said compound is
2 10-(2-Hydroxyethyl)-N²-(5-indanyl)guanine (HE-TMPG).

1 19. The method of claim 2 wherein said compound is
2 10-(2-Hydroxyethyl)-2-(5-indanylamino)adenine (HE-TMAA).

1 20. The method of claim 2 wherein said compound is
2 10-(2-Hydroxyethyl)-N²-(3-ethyl-4-methylphenyl)- guanine
3 (HE-EMPG).

1 21. The method of claim 2 wherein said compound is
2 10-(2-Hydroxyethyl)-2-(3-ethyl-4-methylanilino)- adenine
3 (HE-EMAA).

1 22. The method of claim 2 wherein said compound is
2 10-(2-Hydroxyethyl)-N²-(3,4-dichlorobenzyl)- guanine (HE-
3 DCBG) .

1 23. The method of claim 2 wherein said compound is
2 10-(2-Hydroxyethyl)-2-(3,4-dichlorobenzylamino)- adenine
3 (HE-DCBA) .


1 24. The method of claim 2 wherein said compound is
2 10-(4-Hydroxybutyl)-N²-(3,4-dichlorobenzyl)- guanine (HB-
3 DCBG) .

1 25. The method of claim 2 wherein said compound is
2 10-(4-Hydroxybutyl)-N₂-(3,4-dichlorobenzylamino)- adenine
3 (HB-DCBA) .


1 26. The method of claim 2 wherein said compound is
2 10-(2-Carboxyethyl)-N₂-(3,4-dichlorobenzyl)- guanine (CE-
3 DCBG) .

1 27. The method of claim 2 wherein said compound is
2 10-(2-Aminoethyl)-2-(3,4-dichlorobenzyl)guanine (AE-DCBG) .

1 28. A 3-substituted uracil compound, or
2 pharmaceutically acceptable salt thereof, having the formula



4 wherein R₁ is (CH₂)_nOH, CH₂CHOHCH₂OH, CH₂CHOHCH₃,
5 (CH₂)_mCO₂H, or (CH₂)_nNH₂, n is 2, 3, 4, or 5 and m is 1, 2, 3,
6 or 4; and R₂ is an indanyl,



9 where R₃ and R₄ are H, alkyl, halo, or any other
10 hydrophobic constituents.

1 29. The compound of claim 28 wherein the 3-
2 substituted uracil is 3-(2-Hydroxyethyl)-6-(5-indanylamino)
3 uracil (HE-TMAU).

1 30. The compound of claim 28 wherein the 3-
2 substituted uracil is 3-(2-Hydroxyethyl)-6-(3-ethyl-4-
3 methylanilino) uracil (HE-EMAU).


1 31. The compound of claim 28 wherein the 3-
2 substituted uracil is 3-(2-Hydroxyethyl)-6-(3,4-
3 dichlorobenzylamino) uracil (HE-DCAU).

1 32. The compound of claim 28 wherein the 3-
2 substituted uracil is 3-(4-Hydroxybutyl)-6-(5-indanylamino)
3 uracil (HB-TMAU).


1 33. The compound of claim 28 wherein the 3-
2 substituted uracil is 3-(Carboxymethyl)-6-(5-indanylamino)
3 uracil (CM-TMAU).

1 34. The compound of claim 28 wherein the 3-
2 substituted uracil is 3-(Aminoethyl)-6-(5-indanylamino)
3 uracil (AE-TMAU).

1 35. A 3-substituted isocytosine compound, or
2 pharmaceutically acceptable salt thereof, having the formula



4 wherein R_1 is $(CH_2)_nOH$, $CH_2CHOHCH_2OH$, $CH_2CHOHCH_3$,
5 $(CH_2)_mCO_2H$, or $(CH_2)_nNH_2$, n is 2, 3, 4, or 5 and m is 1, 2, 3,
6 or 4; and R_2 is an indanyl,



9 where R_3 and R_4 are H, alkyl, halo, or any other
10 hydrophobic constituents.


1 36. The compound of claim 35 wherein the 3-
2 substituted isocytosine is 3-(2-Hydroxyethyl)-6-(5-
3 indanylamino) isocytosine (HE-TMAiC).

1 37. The compound of claim 35 wherein the 3-
2 substituted isocytosine is 3-(2-Hydroxyethyl)-6-(3-ethyl-4-
3 methylanilino) isocytosine (HE-EMAiC).

1 38. The compound of claim 35 wherein the 3-
2 substituted isocytosine is 3-(2-Hydroxyethyl)-6-(3,4-
3 dichlorobenzylamino) isocytosine (HE-DCAiC).

1 39. The compound of claim 35 wherein the 3-
2 substituted isocytosine is 3-(4-Hydroxybutyl)-6-(5-
3 indanylamino) isocytosine (HB-TMAiC).

- 1 40. A 10-substituted guanine compound, or
2 pharmaceutically acceptable salt thereof, having the formula



- 4 wherein R_1 is $(CH_2)_nOH$, $CH_2CHOHCH_2OH$, $CH_2CHOHCH_3$,
5 $(CH_2)_mCO_2H$, or $(CH_2)_nNH_2$, n is 2, 3, 4, or 5 and m is 1, 2, 3,
6 or 4; and R_2 is



- 9 where R_3 and R_4 are H, alkyl, halo, or any other
10 hydrophobic constituents.

- 1 41. The compound of claim 40, wherein said compound
2 is 10-(2-Hydroxyethyl)- N^2 -(5-indanyl)guanine (HE-TMPG).

- 1 42. The compound of claim 40, wherein said compound
2 is 10-(2-Hydroxyethyl)- N^2 -(3-ethyl-4-methylphenyl) guanine
3 (HE-EMPG).


- 1 43. The compound of claim 40, wherein said compound
2 is 10-(2-Hydroxyethyl)- N^2 -(3,4-dichlorobenzyl) guanine (HE-
DCBG).

- 1 44. The compound of claim 40, wherein said compound
2 is 10-(4-Hydroxybutyl)- N^2 -(3,4-dichlorobenzyl) guanine (HB-
DCBG).

1 45. The compound of claim 40, wherein said compound
2 is 10-(2-Carboxyethyl)-2-(3,4-dichlorobenzyl) guanine (CE-
3 DCBG).

1 46. The compound of claim 40, wherein said compound
2 is 10-(2-Aminoethyl)-2-(3,4-dichlorobenzyl)guanine (AE-
DCBG).

1 47. A 10-substituted adenine compound, or
2 pharmaceutically acceptable salt thereof, having the formula



4 wherein R₁ is (CH₂)_nOH, CH₂CHOHCH₂OH, CH₂CHOHCH₃,
5 (CH₂)_mCO₂H, or (CH₂)_nNH₂, n is 2, 3, 4, or 5 and m is 1, 2, 3,
6 or 4; and R₂ is



9 where R₃ and R₄ are H, alkyl, halo, or any other
10 hydrophobic constituents.

1 48. The compound of claim 47, wherein said compound
2 is 10-(2-Hydroxyethyl)-2-(5-indanylamino)adenine (HE-TMAA).

1 49. The compound of claim 47, wherein said compound
2 is 10-(2-Hydroxyethyl)-2-(3-ethyl-4-methylanilino) adenine
 (HE-EMAA) .

1 50. The compound of claim 47, wherein said compound
2 is 10-(2-Hydroxyethyl)-2-(3,4-dichlorobenzylamino) adenine
 (HE-DCBA) .

1 51. The compound of claim 47, wherein said compound
2 is 10-(4-Hydroxybutyl)-2-(3,4-dichlorobenzylamino) adenine
 (HB-DCBA) .




FIGURE 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10943**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 31/505,31/52; C07D 239/02,473/00

US CL :514/261,262,269,272,274; 544/276,277,312,321

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/269,272,274; 544/312,321

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Journal of Medicinal Chemistry, Volume 20, No. 9, issued 1977, Neal C. Brown et al, "Inhibitors of Bacillus subtilis DNA Polymerase III. 6-(Arylalkylamino)uracils and 6-Anilinouracils", pages 1186-1189, see entire document, especially Table I.	1-7,10-17 and 28-39
A	Proceedings of the National Academy of Sciences, Volume 67, No. 3, issued November 1970, "6-(p-Hydroxyphenylazo)-uracil: A Selective Inhibitor of Host DNA Replication in Phage-Infected Bacillus subtilis", pages 1454-1461, see entire document.	1-7,10-17 and 28-39

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

18 OCTOBER 1995

Date of mailing of the international search report

28 NOV 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231Authorized officer
CECILIA TSANG

Facsimile No. (703) 305-3230

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10943

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Journal of Medicinal Chemistry, Volume 28, No. 11, issued 1985, T. Nogimori et al, "Synthesis of 6-Anilino-2-thiouracils and Their Inhibition of Human Placenta Iodothyronine Deiodinase", pages 1692-1694, see entire document.	1-7, 10-17 and 28-39

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/10943

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-7(part), 8-17 and 28-39

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/10943

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-7(part), 8-17 and 28-39, drawn to pyrimidines and method of use thereof, classified in 544/312,321; 514/269,272,274.

Group II, claim(s) 1-7(part), 18-27 and 40-51, drawn to purines and method of use thereof, classified in 544/276,277; 514/261, 262.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

A pyrimidine differs significantly from a purine in chemical structure. One skilled in the art would not consider such diverse structures as functional equivalents. Prior art which may anticipate or render obvious I would not do the same for II. Therefore, they do not share a single general inventive concept.